How much does a shot of Eractuzumab produced by Pfizer currently cost?

Elranatamab (Elranatamab), as an innovative BCMA-targeted bispecific T cell-engaging antibody, is one of the advanced drugs currently in the treatment of multiple myeloma. Developed by Pfizer, the drug has been approved for marketing in many countries, including China. Due to its difficulty in research and development, complex production process and outstanding efficacy, drug pricing is relatively high.

Currently in the Chinese market, enantuzumab has been approved for marketing. Although it has not yet been included in the medical insurance directory, it can be purchased through hospital channels or professional pharmacies. Common specifications include 44mg/1.1ml and 76mg/1.9ml. Each box is priced at about RMB 40,000. The actual price will fluctuate due to pricing by medical institutions and regional differences. If the patient uses the starting dose, the dosage per injection is lower and the price is slightly different; after entering the maintenance treatment stage, the cost of a single treatment will increase significantly if the patient is injected at a regular dose.

In comparison, in overseas markets such as the United States, the price of the original version is approximately 8,000 US dollars per injection, which is close to more than 60,000 yuan when converted into RMB, and the price will also be affected by local medical insurance policies, exchange rate changes, supply chain and other factors. Some European and American patients can share the cost of medication through commercial insurance or special drug subsidy programs, but this type of treatment has not yet been fully popularized in China.

It should be noted that there is currently no generic version of eractuzumab on the market in China, so patients can only choose the original drug, which also keeps the overall treatment cost at a high level. At the same time, because it is an immune-targeted therapy drug, it requires long-term repeated injections to maintain disease control.

In the future, if the drug enters the national medical insurance catalog or a localized production version appears, the price is expected to gradually decrease. For patients with a heavy financial burden, you can also pay attention to whether various localities have opened assistance projects or reimbursement pilot mechanisms to reduce drug expenditures.

Reference materials:https://www.drugs.com/mtm/elranatamab.html